NovoCure registered for an initial public offering that could fetch as much as $300 million for its tumor-zapping Optune brain cancer treatment as it awaits a decision from the FDA on a new indication for the device. The federal safety watchdog granted pre-market approval for Optune in April 2011 for adult patients with glioblastoma whose cancer recurred after […]
Oncology
After shelving $69m IPO, Mevion Medical lands $200m, launches China JV
Mevion Medical Systems, which last week shelved plans for a $69 million initial public offering, this week said it raised $200 million from a syndicate of Chinese and U.S. investors and launched a joint venture in the People’s Republic. President & CEO Joe Jachinowski told MassDevice.com today that Mevion, which makes the S250 proton therapy system, […]
Delcath prices $7m follow-on offering
Delcath (NSDQ:DCTH) said today it priced a follow-on offering of 9.3 million units of stock it plans to float at 75¢ per share, slated to bring in $7 million for the company. Each unit in the offering consists of a share of common stock, 0.75 of a Series A warrant to purchase common stock at 87¢, a […]
Navidea lands $60m for Lymphoseek
Edap, GE Healthcare join French-backed $45m liver cancer consortium
Delcath expands Phase II trial
Delcath Systems (NSDQ:DCTH) said it added 2 German research centers to a global Phase II trial of its Chemosat melphalan hepatic delivery system in treating primary liver cancer.
Report: Google’s working on a cancer-detecting pill
Funding: InSightec raises $12.5M from Chinese backers
Israeli device maker InSightec added $12.5 million to its coffers thanks to the support of Chinese backers, the firm’s parent company announced.
Navidea eyes China with partnership for Lymphoseek imaging agent
Navidea Biopharmaceuticals (NYSE:NAVB) is preparing major moves in China with a new alliance that aims to bring its Lymphoseek imaging agent to the country.
Shareholders sue Edap following FDA slip
Exact Sciences lands 1st joint approval through FDA-CMS parallel review
Wisconsin-based Exact Sciences (NSDQ:EXAS) won landmark approval for its Cologuard home colorectal cancer test, becoming the 1st company to successfully navigate a pilot program for parallel review by both FDA and Medicare regulators.